Novocure (NASDAQ: NVCR) has appointed Dr. Nicolas Leupin, M.D., Ph.D., MBA, as its new Chief Medical Officer. The stock moved 1.6% today and is currently trading at $13.71 per share. This move comes as the company seeks to advance its clinical pipeline and treat an expanded patient population.
Asaf Danziger, Novocure's CEO, expressed his enthusiasm about Dr. Leupin's appointment, stating, "It is a pleasure to welcome Dr. Leupin to Novocure as our new chief medical officer. Nicolas brings a wealth of knowledge and experience from some of the most innovative oncology companies in the world, as well as a dedication to patients that is core to Novocure's mission."
Dr. Leupin also shared his excitement about joining Novocure, stating, "2024 is a critical year for Novocure with multiple opportunities on the horizon, and I am excited to be joining a company with such strong capabilities and aspirations to materially advance patient care."
Before joining Novocure, Dr. Leupin served as the Chief Medical Officer at Molecular Partners and Argenx, as well as holding clinical development leadership roles at Celgene. He holds an M.D. from the University of Bern, a Ph.D. from the UBFC-Université in France, and an MBA from Jones International University in the U.S.
Novocure is a global oncology company focused on extending survival in aggressive forms of cancer through the development and commercialization of its innovative therapy, tumor treating fields. The company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma, and pleural mesothelioma. Novocure also has ongoing or completed clinical trials investigating tumor treating fields in various types of cancer.
The company's full 8-K submission is available here.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Revenue (k) | $248,069 | $351,318 | $494,366 | $535,031 | $537,840 | $503,983 |
| Revenue Growth | n/a | 41.62% | 40.72% | 8.23% | 0.53% | -6.29% |
| Operating Margins | -14% | 0% | 6% | -8% | -17% | -44% |
| Net Margins | -26% | -2% | 4% | -11% | -17% | -39% |
| Net Income (k) | -$63,559 | -$7,230 | $19,808 | -$58,351 | -$92,534 | -$197,267 |
| Net Interest Expense (k) | $12,270 | $7,910 | $12,299 | $7,742 | $8,113 | $7,677 |
| Depreciation & Amort. (k) | $9,006 | $8,460 | $9,150 | $10,251 | $10,624 | $10,947 |
| Earnings Per Share | $91828043 | -$0.07 | $0.18 | -$0.56 | -$0.88 | -$1.86 |
| Free Cash Flow (k) | -$8,576 | $16,135 | $84,180 | $58,586 | $9,430 | -$89,188 |
| Capital Expenditures | $6,711 | $10,485 | $14,968 | $24,170 | $21,358 | $26,703 |
| Current Ratio | 4.98 | 5.1 | 8.8 | 7.53 | 7.0 | 6.67 |
NovoCure has consistently negative margins with a negative growth trend, negative expected EPS Growth, and irregular cash flows. On the other hand, the company has growing revenues and increasing reinvestment in the business working in its favor.
